We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

111 hedge funds and large institutions have $408M invested in Enanta Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 28 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 11

71% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 28

13% more funds holding

Funds holding: 98 → 111 (+13)

3% less capital invested

Capital invested by funds: $419M → $408M (-$11.2M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

61% less call options, than puts

Call options by funds: $638K | Put options by funds: $1.62M

Holders
111
Holders Change
+13
Holders Change %
+13.27%
% of All Funds
3.22%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
24
Increased
48
Reduced
28
Closed
11
Calls
$638K
Puts
$1.62M
Net Calls
-$981K
Net Calls Change
-$1.16M

Top Buyers

1
Marshall Wace
Marshall Wace
United Kingdom
+$12.5M
2
SAM
Senzar Asset Management
New York
+$12.4M
3
GC
Guggenheim Capital
Illinois
+$7.68M
4
EAM
Eagle Asset Management
Florida
+$4.92M
5
NI
Numeric Investors
Massachusetts
+$4.43M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$51.4M
2
WSA
Wall Street Associates
California
-$2.4M
3
AAM
Aureus Asset Management
Massachusetts
-$2.39M
4
CCM
Cadence Capital Management
Massachusetts
-$2.38M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
WC
51
Wexford Capital
Florida
$1.26M +$1.27M +31,870 New
BIM
52
BlackRock Investment Management
Delaware
$1.19M +$5.7K +143 +0.5%
GLA
53
Great Lakes Advisors
Illinois
$1.14M +$1.15M +28,862 New
Ameriprise
54
Ameriprise
Minnesota
$1.11M -$164K -4,111 -13%
PI
55
Putnam Investments
Massachusetts
$1.05M +$18.6K +466 +2%
Wells Fargo
56
Wells Fargo
California
$1.03M -$27.2K -683 -3%
Susquehanna International Group
57
Susquehanna International Group
Pennsylvania
$1.02M +$673K +16,877 +192%
GPCM
58
Granite Point Capital Management
Massachusetts
$989K – – –
RFC
59
Regions Financial Corp
Alabama
$976K +$204K +5,126 +26%
Two Sigma Investments
60
Two Sigma Investments
New York
$970K +$319K +8,013 +49%
Federated Hermes
61
Federated Hermes
Pennsylvania
$927K +$927K +23,251 +13,062%
GCP
62
GSA Capital Partners
United Kingdom
$918K +$925K +23,200 New
Tudor Investment Corp
63
Tudor Investment Corp
Connecticut
$815K +$821K +20,596 New
CS
64
Credit Suisse
Switzerland
$755K +$19.3K +483 +3%
California State Teachers Retirement System (CalSTRS)
65
California State Teachers Retirement System (CalSTRS)
California
$754K +$8.29K +208 +1%
SO
66
STRS Ohio
Ohio
$708K +$35.9K +900 +5%
AL
67
Airain Ltd
Guernsey
$705K +$710K +17,808 New
AI
68
Axiom Investors
Connecticut
$619K +$623K +15,640 New
Arrowstreet Capital
69
Arrowstreet Capital
Massachusetts
$606K -$1.02M -25,675 -63%
Prudential Financial
70
Prudential Financial
New Jersey
$592K +$597K +14,970 New
AA
71
ALPS Advisors
Colorado
$590K +$594K +14,900 New
NFA
72
Nationwide Fund Advisors
Ohio
$577K -$1.79K -45 -0.3%
US Bancorp
73
US Bancorp
Minnesota
$566K +$232K +5,817 +68%
TA
74
Teachers Advisors
New York
$560K – – –
BG
75
BlackRock Group
United Kingdom
$556K +$359K +9,011 +179%
1 2
3
4 5

ENTA Hedge Fund Activity: Q3 2014 in Review

111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q3 2014, worth a combined $408M — down 2.7% from $419M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ENTA positions and 11 closed out — a net gain of 13 holders — while 48 added to existing stakes and 28 trimmed.

The largest buyer was Marshall Wace, adding an estimated $12.5M. The largest seller was RA Capital Management, cutting an estimated $51.4M.

  • 111 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q3 2014, up from 98 in Q2 2014.
  • Funds reported $408M of Enanta Pharmaceuticals stock for Q3 2014, down 2.7% quarter-over-quarter.
  • 24 funds opened new Enanta Pharmaceuticals positions in Q3 2014 and 11 closed out, a net change of +13 holders.
  • The largest Enanta Pharmaceuticals buyer in Q3 2014 was Marshall Wace, an estimated $12.5M added.
  • The largest Enanta Pharmaceuticals seller in Q3 2014 was RA Capital Management, an estimated $51.4M sold.

Based on aggregated 13F filings for Q3 2014.